Viral Hepatitis Prevalance and Reactivation Rates in Gastrointestinal Cancers
PDF
Cite
Share
Request
Research
P: 394-397
December 2018

Viral Hepatitis Prevalance and Reactivation Rates in Gastrointestinal Cancers

Med J Bakirkoy 2018;14(4):394-397
1. İstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Genel Cerrahi Kliniği, İstanbul, Türkiye
2. İstanbul Bakırköy Bölgesi Kamu Hastaneleri Birliği Genel Sekreterliği, İstanbul, Türkiye
3. İstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İstanbul, Türkiye
4. İstanbul Bakırköy Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji Kliniği, İstanbul, Türkiye
No information available.
No information available
Received Date: 06.12.2017
Accepted Date: 09.05.2018
Publish Date: 28.12.2018
PDF
Cite
Share
Request

ABSTRACT

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are associated with significant morbidity and mortality among patients with cancer who received cytotoxic chemotherapy. To our knowledge, there are not satisfying available data in regard to hepatitis B surface antigen (HBsAg) positivity ratios in solid cancer patients. Prevalence and reactivation rates of chronic HBV and HCV infections in gastrointestinal cancer patients were retrospectively investigated. Statistical significant relationship was detected for HBsAg positivity in gastric and esophageal cancers (5.67%) and rectum cancer (5.6%). Statistical significant relationship was not detected for HCV. Screenings for viral hepatitis is required in order to prevent treatment discontinuations.

Keywords: Hepatitis B virus, hepatitis C virus, gastric cancer, colon cancer, rectal cancer

References

1
Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012;9:156-66.
2
Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8.
3
Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005;46:1085-9.
4
Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-11.
5
Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 2015;33:2212-20.
6
Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin DL, Parkinet M, al. International classification of diseases for oncology. 3rd ed. (ICD-O-3) Geneva, Switzerland. World Health Organization 2000.
7
Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1-20.
8
Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199-3202.
9
Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 1999;81:69-74.
10
Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001;67:45-50.
11
Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-30.
12
Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74:158-65.
13
de Pree C, Giostra E, Galetto A, Perrin L, Zulian GB. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994;5:861-2.
14
Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004;16:204-5.
15
Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333-40.
16
Kose S, Olmezoglu A, Gozaydin A, Ece G. Seroprevalence of hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr 2011;29:652-5.
17
Wei XL, Qiu MZ, Jin Y, Huang YX, Wang RY, Chen WW, et al. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer 2015;112:1283-90.
2024 ©️ Galenos Publishing House